Biotech | April 06, 2026
Enveda’s experimental oral therapy shows breakthrough results in atopic dermatitis trial
Safety was equally impressive. ENV-294 was well tolerated
Safety was equally impressive. ENV-294 was well tolerated
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Phase I to supply clean energy to five facilities, with long-term plans to power 19 hospitals through a 30 MW renewable network
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
The patient, suffering from calcific severe aortic stenosis—a dangerous narrowing of the heart valve caused by calcium buildup—had run out of standard treatment options
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Subscribe To Our Newsletter & Stay Updated
